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Abstract The purpose of this study is to obtain a con-
sensus for the therapy of B3 lesions. The first International
Consensus Conference on lesions of uncertain malignant
potential in the breast (B3 lesions) including atypical ductal
hyperplasia (ADH), flat epithelial atypia (FEA), classical
lobular neoplasia (LN), papillary lesions (PL), benign
phyllodes tumors (PT), and radial scars (RS) took place in
January 2016 in Zurich, Switzerland organized by the
International Breast Ultrasound School and the Swiss
Minimally Invasive Breast Biopsy group—a subgroup of
the Swiss Society of Senology. Consensus recommenda-
tions for the management and follow-up surveillance of
these B3 lesions were developed and areas of research
priorities were identified. The consensus recommendation
for FEA, LN, PL, and RS diagnosed on core needle biopsy
or vacuum-assisted biopsy (VAB) is to therapeutically
excise the lesion seen on imaging by VAB and no longer
by open surgery, with follow-up surveillance imaging for
5 years. The consensus recommendation for ADH and PT
is, with some exceptions, therapeutic first-line open surgi-
cal excision. Minimally invasive management of selected
B3 lesions with therapeutic VAB is acceptable as an
alternative to first-line surgical excision.
Keywords B3 lesions  Vacuum-assisted biopsy 
Consensus  Breast  Uncertain malignant potential  Breast
surgery
Introduction
Breast lesions classified as lesions of uncertain malignant
potential (B3) are a heterogeneous group of abnormalities
with a borderline histological spectrum, and a variable but
low risk of associated malignancy [1]. They encompass a
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spectrum of histological diagnoses including atypical
ductal hyperplasia (ADH), flat epithelial atypia (FEA),
classical lobular neoplasia (LN), papillary lesions (PL),
benign phyllodes tumors (PT), and radial scars (RS), each
with variable rates of upgrade or long-term increased risk
of breast cancer [2]. Histological diagnosis of a B3 lesion is
made by either core needle biopsy (CNB) mostly using a
14G spring-loaded CNB or by vacuum-assisted biopsy
(VAB) using a 7G–11G device either under ultrasound,
stereotactic, or MRI guidance following informed consent
and local anesthetic. Occasionally it is an incidental finding
on a specimen which has been excised surgically.
Between 4 and 9 % of all CNBs are classified as B3
lesions with numbers increasing due to advances in diag-
nostic imaging such as highly sensitive MRI scanning and
interventional techniques such as VAB [3]. However, the
positive predictive value for malignancy has been falling
(from 29 to 10 %) [4, 5]. Management of B3 lesions pro-
vides a challenge to the multidisciplinary team as diag-
nostic surgical excision is no longer the only available
treatment. Minimally invasive breast biopsy, or VAB,
facilitates removal of larger volumes of tissue than a CNB
equivalent to a small wide local excision and allows the
same diagnostic accuracy as open surgery [6]. For many B3
lesions, instead of surgical excision, VAB may be sufficient
for therapeutic excision which would benefit the patient
and save on healthcare costs by obviating the need for
surgery [7].
The evidence base for appropriate management of B3
lesions in the breast is limited. Practice varies greatly from
country to country. This article provides a review of the
literature for the six different B3 lesions documented
including the analysis of 2 large Swiss B3 histology data-
bases followed by consensus recommendations by an
expert panel taken after a voting by the participants of the
symposium organized by the International Breast Ultra-
sound School (IBUS) and the Swiss MIBB group—a sub-
group of the Swiss Society of Senology in January 2016, in
Zurich, Switzerland.
Methodology
The first International Consensus Conference on lesions of
uncertain malignant potential (B3) was held with interna-
tional experts as part of the IBUS seminar in January 2016
in Zurich. These meetings have been held bi-annually since
2001 with discussion of therapeutic management options
for B3 lesions. The meeting in January 2016 had 90 par-
ticipants with the multidisciplinary expert panel (all the
aforementioned authors) comprising nine radiologists, two
pathologists, one surgeon, and three gynecologists. Each of
the B3 lesions was discussed in turn with reference to the
published literature and the analysis of the MIBB [8]
working group database (histology from 22,072 VABs).
A set of recommendations for the management of B3
breast lesions was prepared building on the current practice
of the Swiss MIBB working group. Recommendations for
management of B3 breast lesions following histological
diagnosis were either: (i) surveillance (defined as 6 monthly
or yearly mammography and/or ultrasound, depending on
the imaging findings) [9], (ii) therapeutic VAB excision, or
(iii) therapeutic open surgical excision. All participants at
the Consensus Conference were invited to vote on all rec-
ommendations and 50 of the 90 participants decided to. 27
(57 %) were radiologists, 2 (4 %) pathologists, 2 (4 %)
surgeons, and 16 (34 %) gynecologists. Nearly two-thirds
of those voting had more than 10 years’ experience in
breast disease diagnosis and management.
There were 3344 ‘‘pure’’ B3 lesions in the MIBB data-
base (15 % of all lesions). Following presentations of each
B3 lesion in detail reviewing the published literature, three
questions were asked in turn:
Q1. If a CNB returned a B3 lesion on histology, should
the lesion be therapeutically excised?
Q2. If so, should it be excised therapeutically using
VAB?
Q3. If the VAB returned a B3 lesion on histology and if
the lesion was completely removed on imaging, is
surveillance acceptable or should a repeat VAB or surgical
excision be performed?
A panel discussion followed the voting and consensus
recommendations were agreed for the management of each
B3 lesion.
Results
Table 1 illustrates the number of cases in each B3 lesion
category that underwent therapeutic surgical excision
compared to those that did not following VAB. Table 2
illustrates the upgrade rate to invasive malignancy for each
B3 lesion in cases that underwent therapeutic open surgical
excision following VAB. Table 3 documents the voting
results for each of the B3 lesions and Table 4 shows the
overall consensus recommendations for the management of
B3 lesions.
Atypical ductal hyperplasia
The histopathologic features of ADH are essentially those
of low-grade ductal carcinoma in situ (DCIS). If less than
2 mm, the lesion is classified as ADH and if more than
2 mm, it is classified as low-grade DCIS [10, 11]. This is
the fundamental problem of ADH diagnosed by CNB
where often only parts of the lesion have been excised as
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VAB or surgical excision may upgrade the diagnosis from
a B3 to a B5a lesion and this is why most guidelines rec-
ommend surgical excision following a CNB diagnosis of
ADH [12]. Stereotactic VAB underestimation rates range
from 9 to 58 % [13–25]. Even with complete removal of
malignant microcalcifications by VAB, underestimation
rates up to 17 % are documented [26–29]. The highest
underestimation rates (22–65 %) are published for ultra-
sound-guided 14G CNB [21, 22, 25, 30–34] while ultra-
sound-guided VABs have much lower rates of
underestimation (0–22 %) [33, 35]. Grady et al. found no
underestimation in lesions completely removed by 8 G
ultrasound-guided VAB [35]. For MRI-guided VAB only
two studies exist regarding underestimation of ADH
showing underestimation rates of 32 and 38 %, respec-
tively [36, 37].
In studies analyzing patients on surveillance without
surgical treatment following a VAB diagnosis of ADH,
long-term upgrade rates to invasive breast cancer of 3–8 %
are reported [19, 26]. After therapeutic surgical excision of
ADH, patients had a fourfold increased risk of developing
breast cancer in either breast with a cumulative incidence
of 30 % in 25 years [10, 11, 38, 39]. Currently, there is
very little data to indicate that lesions smaller than 6 mm
completely excised by VAB with less than 2 foci of ADH
may safely avoid surgery [14, 19, 21, 26, 40].
736 cases of ADH from the MIBB database were
reviewed. 439 (60 %) had subsequent therapeutic open
surgical excision following VAB (Table 1) with an
upgrade rate of 5 % (22/439) to invasive malignancy (B5b)
(Table 2).
If a CNB returned ADH on histology
100 % of the participants thought the lesion should be
excised. 24 % thought therapeutic VAB excision was
acceptable and 73 % thought therapeutic open surgical
excision should be performed.
If a VAB returned ADH on histology
51 % of the participants thought that therapeutic open
surgical excision should be performed and 42 % thought
that surveillance was adequate (Table 3).
Consensus recommendation
A lesion containing ADH which is visible on imaging
should undergo therapeutic open surgical excision. If a
unifocal ADH lesion1 has been completely removed by
VAB, surveillance is justified. Otherwise open surgery is
still recommended (Table 4).
Flat epithelial atypia
FEA is defined as a neoplastic proliferation of the terminal
ductulo-lobular units (TDLU) by a few layers of cells with
low-grade (monomorphic) atypia [2, 41, 42]. Histopathol-
ogy of FEA lesions encompasses the proliferation of round
and uniform cells (defined as low-grade atypia) exhibiting
inconspicuous nuclei [2, 41, 42]. There is often associated
calcification. An FEA lesion lacks secondary architecture
such as roman bridges or cellular tufts and exhibits a
characteristic immunophenotype of negative low-molecu-
lar weight cytokeratins and high regulation of estrogen
receptors [2, 41, 42]. The mammographic appearance of
FEA is mostly seen as microcalcifications which are
irregular and branching with accompanying marked duct
dilatation [2, 41, 42]. Coexisting lesions both on imaging
and on histopathology encompass classical LN, other
benign columnar cell lesions, low-grade intraductal
Table 1 MIBB (VAB only cases) database records indicating numbers of the different B3 lesions that underwent therapeutic surgical excision
following VAB and those that did not
N Number of cases without
therapeutic open surgical excision
Number of cases with therapeutic
open surgical excision
unknown
Atypical ductal hyperplasia 736 239 (33 %) 439 (60 %) 58 (8 %)
Flat epithelial atypia 773 521 (67 %) 177 (23 %) 75 (10 %)
Classical lobular neoplasia 546 313 (57 %) 191 (35 %) 42 (8 %)
Papillary lesion 954 683 (72 %) 154 (16 %) 117 (12 %)
Benign phyllodes tumor 18 13 (72 %) 3 (17 %) 2 (11 %)
Radial scar 317 235 (74 %) 46 (15 %) 36 (11 %)
Total 3344 2004 1010 330
1 Focal ADH is not defined in the WHO classification and
mentioning the exact dimension of ADH lesions below 2 mm is not
mandatory. However recent literature data suggest, that ADH lesions
(less than 2 mm in extension max. 2 cross sections) may not have to
undergo surgical excision. These data need further validation.
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proliferations such as ADH/DCIS, or tubular carcinoma
[2, 41, 42].
The risk of developing breast cancer with a diagnosis of
FEA is estimated at 1–2 times higher than thosewithout FEA
[2, 41, 42]. ADH andDCIS are themost frequent pathologies
found following surgical excision with their incidence
varying from 0 to 40 %. Underestimation rates are between
0–20 % if FEA is diagnosed on core biopsy and are very
similar if diagnosed on VAB (0–21 %) [43–48]. Current
German (AGO) 2015 guidelines [12], do not recommend
therapeutic open surgical excision of FEA diagnosed on
CNB or VAB if the lesion is small (maximum 2 TDLU) and
the imaging abnormality was completely removed by VAB.
Surgical excision is recommended if there is radiopatho-
logical discrepancy, if the lesion is visible on imaging and the
imaging classification is BIRADS 4. For BIRADS 3 lesions,
completely removed byVAB, open surgery is not considered
necessary [43–48].
773 cases of FEA from the MIBB database were
reviewed. 177 (23 %) had subsequent therapeutic open
surgical excision following VAB (Table 1) with an
upgrade rate of 9 % (16/191) to invasive malignancy (B5b)
(Table 2).
If a CNB returned FEA on histology
97 % of the participants thought the lesion should be
excised. 70 % thought therapeutic VAB excision was
acceptable and 27 % thought therapeutic open surgical
excision should be performed.
If a VAB returned FEA on histology
3 % of the participants thought that therapeutic open sur-
gical excision should be performed and 94 % thought that
surveillance was adequate (Table 3).
Consensus recommendation
A lesion containing FEA, which is visible on imaging
should undergo therapeutic excision with VAB. Thereafter
surveillance is justified (Table 4).
Table 2 Illustrates the upgrade rate to invasive malignancy for each B3 lesion in cases that underwent therapeutic open surgical excision
following VAB
Number of cases with therapeutic
open surgical excision
Upgrade rate Numbers upgraded
to DCIS (B5a)
Numbers upgraded to
invasive malignancy (B5b)
Atypical ductal hyperplasia 439 121 (27.6 %) 99 (22.6 %) 22 (5.0 %)
Flat epithelial atypia 177 35 (19.8 %) 19 (10.7 %) 16 (9.0 %)
Classic lobular neoplasia 191 48 (25.1 %) 24 (12.6 %) 24 (12.6 %)
Papillary lesion 154 12 (7.8 %) 8 (5.2 %) 4 (2.6 %)
Phyllodes tumor 3 0 (0 %) 0 (0 %) 0 (0 %)
Radial scar 46 5 (10.9 %) 4 (8.7 %) 1 (2.2 %)
Total 1010 221 (21.9 %) 155 (15.3 %) 67 (6.6 %)
Table 3 Illustrates the voting results for each of the B3 lesions
If a histological diagnosis of a B3
lesion is made on CNB
If the B3 lesion should be excised If a B3 lesion has been therapeutically excised on
VAB
The lesion
should be
excised?
The
lesion
should
not be
excised?
No
vote
Therapeutic
VAB is
acceptable?
Therapeutic
open surgical
excision
should be
performed?
No
vote
An open
re-excision
should be
performed?
A repeat
VAB
should be
performed?
Surveillance
is
acceptable?
No vote
ADH 46 (100 %) 0 (0 %) 0 (0 %) 11 (24 %) 33 (73 %) 1 (2 %) 23 (51 %) 1 (2 %) 19 (42 %) 2 (4.4 %)
FEA 36 (97 %) 0 (0 %) 1 (3 %) 26 (70 %) 10 (27 %) 1 (3 %) 1 (3 %) 1 (3 %) 36 (94 %) 0 (0 %)
LN 32 (91 %) 1 (3 %) 2 (6 %) 19 (58 %) 14 (42 %) 0 (0 %) 5 (13 %) 0 (0 %) 33 (87 %) 0 (0 %)
PL 40 (100 %) 0 (0 %) 0 (0 %) 32 (84 %) 4 (11 %) 2 (5 %) 4 (9 %) 0 (0 %) 39 (91 %) 0 (0 %)
PT 32 (91 %) 1 (3 %) 2 (6 %) 19 (51 %) 17 (46 %) 1 (3 %) 5 (11 %) 1 (2 %) 34 (83 %) 1 (2 %)
RS 41 (85 %) 4 (8 %) 3 (6 %) 33 (72 %) 12 (26 %) 1 (2 %) 1 (2 %) 0 (0 %) 47 (98 %) 0 (0 %)
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Classical lobular neoplasia
Classical LN encompasses a spectrum of atypical epithelial
proliferations in the TDLU of the breast [2, 41, 42]. The
histology consists of non-cohesive proliferating epithelial
cells with or without pagetoid involvement of the terminal
ducts [2, 41, 42]. There are several nomenclatures used for
LN: The classical type of LN covers all lobular lesions,
which develop in the TDLU except those with pleomorphic
or extensive variants. The older nomenclature of atypical
lobular hyperplasia (ALH) and lobular carcinoma in situ
(LCIS) refers to the same lesion but to different extents,
defined as ALH if less than 50 % of the given TDLU are
involved and LCIS if more than 50 % is involved
[2, 41, 42]. The World Health Organization (WHO) also
applies the term lobular intraepithelial lesion (LIN), which
can be classified as LIN 1, 2, and 3, with LIN 1 formally
being equivalent to ALH, LIN2 to LCIS, and LIN3 to the
pleomorphic or extensive LN variants with or without
necrosis [2, 41, 42]. MIBB classification of lobular neo-
plasia categorizes all lesions (classical LN, ALH, LCIS,
LIN1, LIN2) as B3, but LIN 3 or pleomorphic LN or those
with extensive necrosis are classified as B5a. The MIBB
classification and the WHO recommend the use of the
histological terms classical LN as B3 and pleomorphic LN
as B5a [2, 12].
The incidence of classical LN has been increasing and
varies from 0.5 to 4 %. It can occur at all ages but pre-
dominantly in premenopausal women. Most lesions present
incidentally without any palpable mass and less than half of
classical LN lesions have associated calcification. Pub-
lished data on the risk of developing breast cancer after
diagnosis on CNB or VAB show, a relative risk of 1–2 %
per year, 15–17 % after 15 years, and 35 % after 35 years
with relatively equal rates of ipsi- and contralateral breast
cancer (8.7 and 6.7 %, respectively) [2, 49–53]. The
upgrade rate after classical LN diagnosis on CB or VAB is
variable in the literature, ranging from 0 to 50 % which can
at least partially be explained by variation in study design
and inconsistent use of ALH, LCIS, and LN nomenclatures
[2, 41]. In one study, underestimation was found to be 4 %
in classical LN cases when LN was an incidental finding
and 18 %, when LN represented the radiologic targets by
D’Alfonso et al. [50]. Higher upgrade rates were associated
with cases that demonstrated mass lesions and calcification
on imaging or with radiopathological discordance. Lower
underestimation rates were detected in classical LN cases,
where no residual calcification was found after biopsy,
calcification was incidental, and there was complete con-
cordance between histological and imaging findings
[2, 41, 50].
The WHO recommends surgical excision after classical
LN diagnosis on CNB or VAB if there is another B3
lesion present, if another coexisting lesion warrants
excision alone, if there is a mass lesion on imaging, or in
any case of radiopathological discordance [2, 41]. The
German AGO 2015 guidelines favor open excision only if
there is a B5a component, if classical LN is extensive, in
the presence of necrosis on the CNB or VAB, or in cases
of discordance with imaging [12]. Open surgical excision
is therefore not considered necessary if there is a complete
concordance between histology and imaging, if the
imaging finding is classified as BIRADS 3, or of LN is a
focal finding and is not associated with calcifications
[2, 12, 41].
546 cases of classical LN from the MIBB database were
reviewed. 191 (35 %) had subsequent therapeutic open
surgical excision following VAB (Table 1) with an
upgrade rate of 12.6 % (24/191) to invasive malignancy
(B5b) (Table 2).
Table 4 Consensus recommendations for the management of B3 lesions. FEA flat epithelial atypia, RS radial scar, PL papillary lesion, PT
phyllodes tumor, LN classical lobular neoplasia, ADH atypical ductal hyperplasia, VAB Vacuum assisted biopsy, OE Open excision
Diagnosis made by CNB Diagnosis made by VAB
ADH OE. VAB in unifocal ADH in small lesions could
be justified
OE. If the lesion has been removed completely and only focal ADH
with calcifications exists, surveillance could be justified
FEA VAB or OE of visible lesion surveillance is justified if the radiological lesion has been removed
LNa OE or VAB (remove US-visible lesion) OE. High risk follow-up if the radiological lesion has been removed
PLb Remove larger or symptomatic (and especially peripheral) Papillomas. VAB is Acceptable
PT OE. Free margins in borderline and malignant PT’s Follow up in completely excised benign PT’s
surveillance is justified
RS VAB or OE of visible lesion surveillance is justified if the radiological lesion has been removed
a LN only classical type. Pleomorphic LN should not be classified as B3 lesion. It is rather being treated like a high grade DCIS
b PL with atypia: Such a lesion should not be classified as papilloma, but rather as FEA or ADH according to the type of atypia found
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If a CNB returned classical LN on histology
91 % of the participants thought the lesion should be
excised. 58 % thought therapeutic VAB excision was
acceptable and 42 % thought therapeutic open surgical
excision should be performed.
If a VAB returned classical LN on histology
13 % of the participants thought that therapeutic open
surgical excision should be performed and 87 % thought
that surveillance was adequate (Table 3).
Consensus recommendation
A lesion containing classical LN lesion, which is visible on
imaging should undergo therapeutic excision with VAB.
Thereafter surveillance is justified (Table 4).
Papillary lesion
PLs represent up to 5 % of all biopsied breast lesions
[54–57]. The term PL comprises a heterogeneous group of
epithelial lesions such as intraductal papilloma, intraductal
papilloma with ADH, intraductal papilloma with DCIS,
papillary DCIS, encapsulated papillary carcinoma, solid
papillary carcinoma, and invasive papillary carcinoma [2].
PLs demonstrate intra-lesional heterogeneity and can be
associated with small foci of ADH or DCIS within the PL
or in the adjacent tissue which may be missed by limited
sampling with CNB. When describing PL, only PL without
atypia should be considered, as a lesion with atypia should
be considered within the higher class lesions (e.g., ADH)
and offered therapeutic open surgical excision.
Upgrade rates after surgical excision of benign papil-
lomata diagnosed following CNB or VAB vary from 0 to
28 % with atypical cells and from 0 to 20 % for invasive
cancer [58–60]. Generally, understaging of invasive
malignancy is reduced if multiple biopsy cores are taken or
if a larger biopsy needles are employed such as in VAB.
Only one study by Chang et al. evaluated the accuracy of
VAB in PL without atypia by open surgical excision fol-
lowing VAB with no upgrade to malignancy but an
upgrade of 18.3 % to atypia [61]. Most studies following
up VAB excision of PL without atypia did not observe any
upgrade to malignancy with at least 2 years of surveillance
[60, 62, 63]. One recorded a minimal underestimation of
1.4 % [64] and another 3.2 % [65].
The upgrade rate to malignancy following VAB in the
MIBB database was 7.7 % for PL without atypia which is
higher than in the documented literature. One reason might
be the fact that the size of the PL was not recorded,
implying that some PL might not have been completely
removed. Mosier et al. removed only lesions smaller than
15 mm (range 3–15 mm) to ensure the complete removal
of the PL [62]. With this approach, they had no upgrades to
malignancy after nearly 9 years. Due to difficulties in
excluding malignancy with small tissue samples at CNB,
heterogeneity of PLs, and an upgrade rate to carcinoma of
up to 20 % [58], the current recommendation is to com-
pletely remove PL without atypia, either by surgery or
VAB [58–60].
954 cases of PL from the MIBB database have been
reviewed. 154 (16 %) had subsequent therapeutic open
surgical excision following VAB (Table 1) with an
upgrade rate of 2.6 % (4/154) to invasive malignancy
(B5b) (Table 2).
If a CNB returned PL on histology
100 % of the participants thought the lesion should be
excised. 84 % thought therapeutic VAB excision was
acceptable and 11 % thought therapeutic open surgical
excision should be performed.
If a VAB returned PL on histology
9 % of the participants thought that therapeutic open sur-
gical excision should be performed and 91 % thought that
surveillance was adequate (Table 3).
Consensus recommendation
A PL lesion, which is visible on imaging should undergo
therapeutic excision with VAB. Thereafter surveillance is
justified (Table 4).
Phyllodes tumor
PTs are rare fibroepithelial neoplasms accounting for less
than 1 % of primary breast tumors [2, 66]. Histologically,
they are classified as benign, borderline, and malignant
with the first two subtypes categorized as B3 lesions [67].
The majority of PTs are benign, (63–78 %) with borderline
PTs diagnosed in 11–30 % of cases [2]. Incidence is
highest in women aged 40–51 years [68, 69]. Overlapping
clinical, radiological, and histopathological features may
make differentiation from benign fibroadenomata chal-
lenging at times, however accurate preoperative diagnosis
is essential to establish the most appropriate therapeutic
approach.
Underestimation rates of PTs following CNB range
from 8 to 39 % (mean 20 %) [70, 71].Concordance rates
between CNB and surgical excision for benign and bor-
derline/malignant PTs are between 38.5 and 82 % and
74.7–100 %, respectively [72], with higher concordance of
208 Breast Cancer Res Treat (2016) 159:203–213
123
up to 90 % following VAB [73]. Youk et al. documented
upgrades from benign to malignant PTs in 8.7 % of
patients, with higher underestimation rates found in pre-
excisional ultrasound BIRADS 4 lesions and higher clas-
sifications [73]. Recurrence rates for benign PTs are similar
following ultrasound -guided VAB (0–19.4 %) and surgi-
cal excision (5–17 %) [74–76], but higher for borderline
PTs following surgical excision (14–25 %) [77, 78]. The
majority of published studies recommend open surgical
excision for all histological PT-subtypes, despite the fact
that the recurrence rate for benign PTs after VAB and
surgical excision do not vary significantly [73–76, 79–81].
18 cases of PT from the MIBB database have been
reviewed. 3 (17 %) had subsequent therapeutic open sur-
gical excision following VAB (Table 1) with an upgrade
rate of 0 % to invasive malignancy (B5b) (Table 2).
If a CNB returned PT on histology
91 % of the participants thought the lesion should be
excised. 51 % thought therapeutic VAB excision was
acceptable and 46 % thought therapeutic open surgical
excision should be performed.
If a VAB returned PT on histology
11 % of the participants thought that therapeutic open
surgical excision should be performed and 83 % thought
that surveillance was adequate (Table 3).
Consensus recommendation
A PT lesion, which is visible on imaging should undergo
therapeutic open surgical excision with clear margins. If a
VAB shows a benign PT, surveillance is justified, while
borderline and malignant PTs require re-excision to obtain
clear margins (Table 4).
Radial scar
RS or complex sclerosing lesions (CSL) of the breast are
characterized by a stellate-like distortion. The nomenclature
depends on the size of the lesion which is defined as radial
scar if the focus is less than 1 cm or complex sclerosing
lesion if over 1 cm [2, 41]. Histopathology of a RS/CSL
involves a stellate-like elastosis with or without the presence
of associated lobulocentric cysts, usual ductal hyperplasia,
adenosis, and microcalcifications. The adenosis may evolve
the elastic fibers resulting in entrapped glands, which may
mimic a highly differentiated neoplastic glandular prolifer-
ation [2, 41]. Onmammography, RS/CSLmostly appear as a
stellate lesion which mimics an invasive carcinoma. The
incidence is variable being 4–9 % in population-based
pathology databases, but being significantly higher, up to
63 % in sole pathology literature [2, 41].
The prognosis of RS/CSL depends on the presence of
associated atypia [2, 41, 82–87]. Based on correlation
between imaging and pathology, RS/CSL without atypia
following CNS or VAB are unlikely to have malignancy in
the surgical excision specimen if the lesion is less than
6 mm on imaging and the patients are younger than
40 years or older than 60 years [82–87]. The relative risk
of developing breast cancer given the presence of a RS/
CSL without atypia varies between 1.1 and 3.0 % [88–90].
Conversely, RS/CSL showing cytological or histological
atypia, have a higher relative risk of 2.8–6.7 % particularly
in patients over 50 years of age [88–90]. Underestimation
rates for pure RS/CSL vary between 1 and 28 % following
CNB and 8 % following VAB [2, 41, 82–87]. The AGO
2015 and WHO 2012 guidelines recommend surveillance if
the imaging findings have been completely excised at VAB
and no atypia was found in the histological examination.
RS/CSL with atypia on histology following CNB/VAB
should undergo therapeutic open surgical excision
[2, 12, 41, 88–90].
317 cases of RS/CSL from the MIBB database have
been reviewed. 46 (15 %) had subsequent therapeutic open
surgical excision following VAB (Table 1) with an
upgrade rate of 2 % (1/46) to invasive malignancy (B5b)
(Table 2).
If a CNB returned RS/CSL on histology
85 % of the participants thought the lesion should be
excised. 72 % thought therapeutic VAB excision was
acceptable and 26 % thought therapeutic open surgical
excision should be performed.
If a VAB returned RS/CSL on histology
2 % of the participants thought that therapeutic open sur-
gical excision should be performed and 98 % thought that
surveillance was adequate (Table 3).
Consensus recommendation
A RS/CSL lesion, which is visible on imaging should
undergo therapeutic excision with VAB. Thereafter
surveillance is justified (Table 4).
Discussion
The expert consensus panel and participants agreed that for
most of the B3 lesions (except for ADH and PT), surgery
can be avoided and therapeutic excision with VAB of a
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lesion which is visible on imaging is an acceptable alterna-
tive. However, as data are lacking at present the panel still
recommends open surgery in cases of ADH. As more data
on the minimally invasive conservative management of B3
lesions become available, a more conservative approach
may also be justified in cases of ADH. The outcome from
this consensus meeting is a progressive move forward to a
more conservative approach to managing these lesions in
which open surgery can potentially be avoided. Studies
following a diagnosis of low-grade DCIS have shown
excellent survival rates of more than 98 % at ten years after
diagnosis without surgery [91, 92] which have prompted
randomized phase III trials for surgery versus no surgery in
low- and intermediate-grade DCIS [93, 94]. Therefore it is
becoming clear, that it is even more reasonable to try to
avoid unnecessary open surgery or overtreatment in some
women. It is important to emphasize that these recom-
mendations cannot exclude a false-negative diagnosis in
every individual patient and each case should be discussed
on an individual basis with a multidisciplinary team taking
into account the imaging features, lesion size, practicality
and technical feasibility of minimally invasive manage-
ment, patient demographics, and patient preference.
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